Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23119119 | 0.94 | GNAI3 (0.36) | DPP4HSP90AA1HSP90AB1TDP1GNAI3 | |
| SCHEMBL23328075 | 0.88 | GNAI3 (0.40) | TDP1GNAI3GNAO1GNAI1LMNA | |
| SCHEMBL24591345 | 0.78 | L3MBTL1 (0.36) | TDP1GNAI3GNAO1GNAI1LMNA | |
| SCHEMBL14892058 | 0.78 | RIPK1 (0.44) | DPP4HSP90AA1HSP90AB1TDP1CNR1 | |
| SCHEMBL21339854 | 0.78 | DPP4 (0.40) | DPP4GNAI3GNAO1GNAI1 | |
| SCHEMBL9963903 | 0.77 | HSP90AA1 (0.41) | DPP4HSP90AA1HSP90AB1LMNA | |
| SCHEMBL24591412 | 0.76 | L3MBTL1 (0.39) | TDP1GNAI3GNAO1GNAI1 | |
| SCHEMBL22453255 | 0.75 | L3MBTL1 (0.46) | TDP1LMNA | |
| SCHEMBL18474665 | 0.75 | L3MBTL1 (0.42) | TDP1LMNA | |
| SCHEMBL12452605 | 0.73 | HSP90AA1 (0.40) | DPP4HSP90AA1HSP90AB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200071296-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071296-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | DPP4 1732/4885HSP90AA1 315/4885HSP90AB1 55/4885 |
| US-11053216-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | DPP4 1732/4885HSP90AA1 315/4885HSP90AB1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.